Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
19.49
+0.91 (4.90%)
At close: Oct 24, 2025, 4:00 PM EDT
19.88
+0.39 (2.00%)
Pre-market: Oct 27, 2025, 5:56 AM EDT
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $2.00M in the quarter ending June 30, 2025, a decrease of -9.51%. This brings the company's revenue in the last twelve months to $9.83M, down -21.09% year-over-year. In the year 2024, Tonix Pharmaceuticals Holding had annual revenue of $10.09M with 29.94% growth.
Revenue (ttm)
$9.83M
Revenue Growth
-21.09%
P/S Ratio
8.00
Revenue / Employee
$121,370
Employees
81
Market Cap
170.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.09M | 2.33M | 29.94% |
| Dec 31, 2023 | 7.77M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TNXP News
- 4 days ago - Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital - GlobeNewsWire
- 5 days ago - Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence - GlobeNewsWire
- 9 days ago - Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025 - GlobeNewsWire
- 12 days ago - Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation - GlobeNewsWire
- 17 days ago - Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025 - GlobeNewsWire
- 26 days ago - Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access - GlobeNewsWire
- 27 days ago - Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026 - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder - GlobeNewsWire